146 related articles for article (PubMed ID: 18320148)
1. Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide-dexamethasone.
Magalini F; Stella A; Sansoni P
Intern Emerg Med; 2008 Dec; 3(4):383-5. PubMed ID: 18320148
[No Abstract] [Full Text] [Related]
2. Trials investigate first-line thalidomide in multiple myeloma.
Owen OG
Lancet Oncol; 2005 Jan; 6(1):6. PubMed ID: 15672486
[No Abstract] [Full Text] [Related]
3. Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.
Boga C; Ozdogu H; Yeral M; Kizilkilic E; Tamer L
J Support Oncol; 2007 Jun; 5(6):256. PubMed ID: 17624049
[No Abstract] [Full Text] [Related]
4. Thalidomide and thrombosis. A meta-analysis.
El Accaoui RN; Shamseddeen WA; Taher AT
Thromb Haemost; 2007 Jun; 97(6):1031-6. PubMed ID: 17549307
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
[TBL] [Abstract][Full Text] [Related]
6. Thrombosis in multiple myeloma (MM).
Cesarman-Maus G; Braggio E; Fonseca R
Hematology; 2012 Apr; 17 Suppl 1(0 1):S177-80. PubMed ID: 22507814
[TBL] [Abstract][Full Text] [Related]
7. Dermatologic side effects of thalidomide in patients with multiple myeloma.
Hall VC; El-Azhary RA; Bouwhuis S; Rajkumar SV
J Am Acad Dermatol; 2003 Apr; 48(4):548-52. PubMed ID: 12664018
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide in multiple myeloma: current status and future prospects.
Cavenagh JD; Oakervee H;
Br J Haematol; 2003 Jan; 120(1):18-26. PubMed ID: 12492572
[No Abstract] [Full Text] [Related]
9. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K
Semin Hematol; 2003 Oct; 40(4 Suppl 4):3-7. PubMed ID: 15015890
[TBL] [Abstract][Full Text] [Related]
10. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.
Dimopoulos MA; Hamilos G; Zomas A; Gika D; Efstathiou E; Grigoraki V; Poziopoulos C; Xilouri I; Zorzou MP; Anagnostopoulos N; Anagnostopoulos A
Hematol J; 2004; 5(2):112-7. PubMed ID: 15048060
[TBL] [Abstract][Full Text] [Related]
11. Hematology: Is thalidomide combination a new option for myeloma?
Palumbo A
Nat Rev Clin Oncol; 2010 Aug; 7(8):425-6. PubMed ID: 20668477
[No Abstract] [Full Text] [Related]
12. The future role of thalidomide in multiple myeloma.
Boccadoro M; Blade J; Attal M; Palumbo A
Acta Haematol; 2005; 114 Suppl 1():18-22. PubMed ID: 16166768
[TBL] [Abstract][Full Text] [Related]
13. Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma.
Wölfler A; Bauer F; Zollner G; Weber K; Sill H; Linkesch W
Haematologica; 2003 Apr; 88(4):ELT12. PubMed ID: 12681989
[No Abstract] [Full Text] [Related]
14. Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.
Mazzotta S; Gozzetti A; Pirrotta MT; Bocchia M; Sammassimo S; Bucalossi A; Lauria F
Leuk Lymphoma; 2005 Dec; 46(12):1837-8. PubMed ID: 16263590
[TBL] [Abstract][Full Text] [Related]
15. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA
Leukemia; 2008 Dec; 22(12):2247-56. PubMed ID: 18769451
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R
J Clin Oncol; 2003 Jan; 21(1):16-9. PubMed ID: 12506164
[TBL] [Abstract][Full Text] [Related]
17. [Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone].
Miyazawa Y; Irisawa H; Uchiumi H; Saitoh T; Handa H; Matsushima T; Tsukamoto N; Karasawa M; Murakami H; Nojima Y
Rinsho Ketsueki; 2006 Jul; 47(7):656-60. PubMed ID: 16910577
[TBL] [Abstract][Full Text] [Related]
18. [Thalidomide treatment in multiple myeloma].
Hattori Y
Rinsho Ketsueki; 2003 May; 44(5):302-12. PubMed ID: 12822404
[No Abstract] [Full Text] [Related]
19. Reversible dementia due to thalidomide therapy for multiple myeloma.
Morgan AE; Smith WK; Levenson JL
N Engl J Med; 2003 May; 348(18):1821-2. PubMed ID: 12724497
[No Abstract] [Full Text] [Related]
20. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
